Advertisement
REGN or VRTX or ZTS
Which Stock Would AI Choose? Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- REGN shows mixed recent performance with promising Phase 3 obesity drug data, trading at a forward P/E of around 18 amid analyst views of undervaluation.
- VRTX leads with strong momentum from positive Phase 3 kidney disease trial results, driving an 8.3% surge and YTD gains of about 8.6%.
- ZTS offers stability in animal health but faces growth concerns, with recent Q4 earnings beats offset by a YTD decline and lower forward P/E near 17-20.
- Market caps stand at ~$82B for REGN, ~$125B for VRTX, and ~$54B for ZTS, reflecting biotech scale versus defensive positioning.
- Recent healthcare sector volatility highlights VRTX's relative outperformance in momentum, while ZTS provides lower beta exposure.
Introduction
This stock comparison examines REGN, VRTX, and ZTS, leaders in biotechnology and animal health. REGN and VRTX focus on human therapeutics for serious diseases, while ZTS dominates veterinary care. Investors seeking growth in innovative pipelines or stability in essential services, and traders eyeing relative performance and market positioning, will benefit from analyzing their recent momentum, valuations, and sector dynamics in the current environment.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) is a leading biotechnology firm discovering, developing, and commercializing medicines for serious diseases like eye disorders, cancer, and inflammatory conditions using proprietary technologies such as VelociSuite. In recent market activity, shares have shown mixed behavior, with short-term cooling after gains but positive longer-term returns around 8-9% over the past year. Key influences include strong Phase 3 results for obesity candidate olatorepatide and expansions in Dupixent approvals, fostering analyst optimism on undervaluation with fair value estimates near $894 versus recent levels around $775. Sentiment reflects pipeline strength amid broader biotech volatility.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX) specializes in transformative therapies for serious diseases, particularly cystic fibrosis, sickle cell disease, and kidney conditions, with a robust pipeline in genetic and rare disorders. Recent weeks have driven notable gains, including an 8.3% surge on Phase 3 success for kidney drug povetacicept showing 52% proteinuria reduction, alongside YTD advances of about 8.6% and monthly outperformance. Trading near $492 with a forward P/E around 21-27, performance benefits from earnings growth projections of 10% and pipeline catalysts, enhancing positive market sentiment despite sector pressures.
ZTS Overview and Recent Performance
Zoetis (ZTS), the world's largest animal health company, develops vaccines, medicines, diagnostics, and technologies for companion animals and livestock across over 100 countries. Shares have faced headwinds in recent activity, with YTD softness around -2% to +4% amid growth scrutiny, though Q4 earnings beat estimates at $1.48 EPS. Trading near $120 with a forward P/E of 17-20, influences include strategic acquisitions like Neogen's genomics unit for $160M and veterinary initiatives, supporting steady demand but highlighting livestock challenges and longer-term declines.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots feature impressive stats like annualized returns up to 279%, win rates exceeding 70% in some cases, and profit factors above 2.0, with examples including +19% on penny stocks and +124% in aerospace sectors. Optimized for current volatility, they employ technical and fundamental analyses for short-term swings or longer trends. Traders can explore and subscribe to these elite performers to enhance strategies—visit the Trending AI Robots page for live rankings and backtested results.
Head-to-Head Comparison
REGN, VRTX, and ZTS operate in healthcare but diverge in models: REGN and VRTX emphasize high-risk biotech innovation in human diseases like obesity and kidneys, while ZTS provides defensive animal health stability. Growth drivers contrast VRTX's recent trial catalysts and 10% earnings outlook against ZTS's modest 4-5% revenue growth. Momentum favors VRTX with superior YTD and monthly gains, versus REGN's mixed trends and ZTS's underperformance. Risks include pipeline failures for biotechs and livestock cycles for ZTS; valuations show ZTS cheapest, VRTX premium for momentum. Sentiment tilts toward VRTX in biotech rotation.
Tickeron AI Verdict
Tickeron’s AI currently favors VRTX based on superior recent momentum from clinical catalysts, consistent YTD outperformance, and robust growth projections amid healthcare trends. While REGN offers undervaluation potential and ZTS stability, VRTX's relative positioning suggests higher probability of near-term upside, though all carry sector risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REGN’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- REGN’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REGN’s TA Score shows that 2 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- REGN’s TA Score: 2 bullish, 6 bearish.
- VRTX’s TA Score: 4 bullish, 3 bearish.
- ZTS’s TA Score: 4 bullish, 4 bearish.
Price Growth
REGN (@Biotechnology) experienced а +0.23% price change this week, while VRTX (@Biotechnology) price change was +1.13% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
REGN is expected to report earnings on Apr 29, 2026.
VRTX is expected to report earnings on May 04, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| REGN | VRTX | ZTS | |
| Capitalization | 79.4B | 112B | 51.5B |
| EBITDA | 5.82B | 4.87B | 4.07B |
| Gain YTD | -2.643 | -2.682 | -2.319 |
| P/E Ratio | 18.09 | 28.80 | 20.33 |
| Revenue | 14.3B | 12B | 9.47B |
| Total Cash | 8.61B | 6.61B | 2.31B |
| Total Debt | 2.71B | 2.03B | 9.24B |
REGN | VRTX | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 60 | 11 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 80 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 75 | 35 | 100 | |
SMR RATING 1..100 | 54 | 40 | 16 | |
PRICE GROWTH RATING 1..100 | 47 | 60 | 62 | |
P/E GROWTH RATING 1..100 | 40 | 53 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as ZTS (30) in the Pharmaceuticals Generic industry, and is significantly better than the same rating for VRTX (80) in the Biotechnology industry. This means that REGN's stock grew similarly to ZTS’s and significantly faster than VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for REGN (75) in the Biotechnology industry, and is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that VRTX's stock grew somewhat faster than REGN’s and somewhat faster than ZTS’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is in the same range as VRTX (40) in the Biotechnology industry, and is somewhat better than the same rating for REGN (54) in the Biotechnology industry. This means that ZTS's stock grew similarly to VRTX’s and somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (47) in the Biotechnology industry is in the same range as VRTX (60) in the Biotechnology industry, and is in the same range as ZTS (62) in the Pharmaceuticals Generic industry. This means that REGN's stock grew similarly to VRTX’s and similarly to ZTS’s over the last 12 months.
REGN's P/E Growth Rating (40) in the Biotechnology industry is in the same range as VRTX (53) in the Biotechnology industry, and is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that REGN's stock grew similarly to VRTX’s and somewhat faster than ZTS’s over the last 12 months.
| REGN | VRTX | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 64% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 52% | 2 days ago 64% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 49% | 2 days ago 62% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 62% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 36% | 2 days ago 54% |
| Advances ODDS (%) | 18 days ago 64% | 5 days ago 63% | 5 days ago 52% |
| Declines ODDS (%) | 3 days ago 51% | 3 days ago 43% | 3 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 49% | N/A | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 30% | 2 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHE | 35.98 | 0.59 | +1.67% |
| Schwab Emerging Markets Equity ETF™ | |||
| JDOC | 57.15 | 0.94 | +1.67% |
| JPMorgan Healthcare Leaders ETF | |||
| HYTI | 19.48 | 0.13 | +0.65% |
| FT Vest High Yield & Target Income ETF | |||
| FIAX | 17.72 | 0.08 | +0.44% |
| Nicholas Fixed Income Alternative ETF | |||
| PJUN | 42.99 | 0.09 | +0.22% |
| Innovator U.S. Equity Power BffrETF™-Jun | |||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with SMMT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +0.61% | ||
| SMMT - REGN | 41% Loosely correlated | +2.99% | ||
| ARQT - REGN | 39% Loosely correlated | +1.49% | ||
| INCY - REGN | 36% Loosely correlated | +2.62% | ||
| IDYA - REGN | 36% Loosely correlated | +4.24% | ||
| GMAB - REGN | 35% Loosely correlated | +0.88% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 52% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||